Decoding the shifts in global diagnostic technology and laboratory efficiency.
Modern laboratories are transitioning from manual nucleic acid extraction to fully automated "sample-to-result" systems. Our OEM solutions integrate robotic liquid handling and real-time PCR to minimize human error and increase diagnostic speed.
Semantic data processing and AI algorithms are now standard in molecular analysis. We provide devices capable of high-fidelity signal detection, allowing for precise quantification of DNA/RNA biomarkers in complex biological matrices.
Point-of-Care Testing (POCT) is the fastest-growing segment. Our R&D focus includes miniaturized molecular devices that deliver hospital-grade accuracy in decentralized settings like clinics and mobile labs.
Healthcare providers across Europe, North America, and emerging markets face a rising demand for specialized genetic testing. Shenzhen BioX Medical Co., Ltd. offers scalable macro solutions that address:
Our role as an exporter involves not just shipping hardware, but providing the "Information Gain" necessary for local distributors to dominate their respective markets.
Established in 2017, BioX Medical is headquartered in Shenzhen, China, the global epicenter for biotechnology innovation. Our 9,000 square meter facility is designed to meet the rigorous demands of international IVD (In-Vitro Diagnostics) manufacturing.
Sqm Factory Space
Expert Professionals
Countries Served
Quality Compliance
Our multidisciplinary team of engineers and laboratory specialists continuously invests in innovation. By integrating advanced automation, data management, and workflow optimization, we develop solutions that redefine analytical accuracy and operational reliability.
We navigate the complexities of CE-IVD, FDA, and local NMPA certifications to ensure your molecular analysis devices are market-ready the moment they arrive.
From UI/UX software localization to physical industrial design, our ODM services allow brands to offer a tailored user experience to their specific regional clinicians.
In an era of logistics uncertainty, we provide robust lead-time guarantees and strategic inventory management to ensure uninterrupted diagnostic testing capacity.
Enhanced detection of multiple pathogens in a single reaction well.
Real-time diagnostic telemetry and remote laboratory management.
Bringing Next-Generation Sequencing capabilities to benchtop analyzers.
Unlike standard manufacturers, we provide a full-stack R&D approach. This includes the mechanical hardware, the optical detection system, the thermal cycling precision, and the proprietary software that interprets fluorescence signals, ensuring a cohesive and high-performance product.
We implement multi-stage quality control. Every device undergoes rigorous thermal uniformity testing and sensitivity validation using standardized control samples. Our ISO 13485 certified processes ensure that every unit leaving our Shenzhen factory performs to clinical standards.
Yes. Our automated systems feature open API architectures and HL7 protocol compatibility, allowing seamless data transfer between the analysis device and the hospital's central management system, improving overall diagnostic workflow.
Depending on the complexity of the customization, prototype development typically takes 3-6 months, followed by rigorous testing and certification phases. We work closely with our partners to accelerate the time-to-market for critical diagnostic tools.
BioX Medical
